Company Profile - ALK-Abello AS


ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies to treat and prevent allergies. The company's allergy immunotherapy product portfolio includes tablets, sublingual or drop-based vaccines, subcutaneous vaccines, and adrenaline auto-injectors to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing ragweed, house dust mite, and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, and venom. The company has subsidiaries in Europe, North America, and Asia-Pacific. ALK is headquartered in Horsholm, Denmark.

Company info

Country (HQ): Denmark
Sector: Pharmaceuticals and Healthcare
Market Cap (US$ m): 2,454
Revenue (US$ m): 638 (2022)

Innovation ranking


Innovation score

Closest peers in the Pharmaceuticals and Healthcare sector

Innovation Ranking


Johnson & Johnson

United States

Pharmaceuticals and Healthcare

F. Hoffmann-La Roche Ltd


Pharmaceuticals and Healthcare

ALK-Abello AS


Pharmaceuticals and Healthcare

EyeGate Pharmaceuticals Inc

United States

Pharmaceuticals and Healthcare

Shin Poong Pharm Co Ltd

South Korea

Pharmaceuticals and Healthcare

Are you ranked? Get the Innovation Ranking Report

  • Company Ranking Report
    • If your company is ranked you can get more detailed information about your ranking through the Innovation Ranking Report
    • Full company scorecard across the 3 pillars and 19 data indicators that make up the ranking score
    • Contextualised information on the company's standing in relation to peers
    • Key takeaways on the company's position in its sector, country and its standing in relation to key industry themes
    • Tips on how to use your ranking to tell a unique and compelling story in your marketing, benchmarking and hiring processes
  • Rosettes
  • Certificate of Achievement
  • Press release
Screenshot of Deal Makers